Inhibition of tumor angiogenesis via blockade of vascular endothelial growth factor either by anti–vascular endothelial growth factor monoclonal antibody (bevacizumab) or tyrosine kinase inhibition (sunitinib, pazopanib, and sorafenib) is associated with increased arterial thrombotic events, including MI (107). Here, VEGFA is linked to neoplasm.